通常说来,许多糖尿病患者会依次经历三级或四级治疗方案,最终会加上胰岛素注射来控制他们的血糖。德克萨斯大学西南医学中心的研究人员认为,这种逐渐增强的治疗策略对于改变糖尿病的发展进程几乎没有什么作用,而且它还意味着患者自己分泌胰岛素的β细胞会持续暴露于高血糖风险之下。
In a study presented last month at the annual meeting of the ADA, UT Southwestern researcher Ildiko Lingvay said two types of more aggressive treatments using insulin and drugs started when patients were initially diagnosed effectively preserved the function of beta cells in a study of 58 patients followed for three years. The regimen included three months of insulin injections combined with metformin for all patients. Then patients were randomly assigned to either the same treatment or a combination of three oral drugs, which continued for more than three years. The study had important limitations, including the small number of patients and the lack of a control group that was followed with standard therapy to compare benefits and side effects.
德克萨斯大学西南医学中心的研究员伊尔迪科·林格维(Ildiko Lingvay)上个月在ADA年度会议上公布了一项研究结果。他说,当患者一开始得到有效诊断并且保留了β细胞的机能时,两类使用了胰岛素和药物的更加激进的治疗方案就可以启动。这项研究涉及58名患者,持续了三年时间。在该治疗方案中,研究人员会对所有患者进行三个月的胰岛素注射和二甲双胍治疗,随后会随机为患者实施同样的治疗方案或是实施由三种口服药组成的组合治疗方案,治疗时间持续了三年多。这项研究存在一些重大的不足之处,包括患者人数少、缺乏后续接受了标准治疗的控制组来比较二者之间的优点和副作用。
【糖尿病治疗新策略】相关文章:
★ 全球氦气供应短缺
最新
2020-09-15
2020-09-15
2020-09-15
2020-09-15
2020-09-15
2020-09-15